Capha Pharmaceuticals Inc.
Capha Pharmaceuticals Inc. (FPSUF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
fpsuf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Capha Pharmaceuticals Inc.You FPSUF | $0M | N/A | — | — |
 American Bio Medica Corporation ABMC | $0M | N/A | — | -$0.03 |
 Acacia Diversified Holdings, Inc. ACCA | $0M | N/A | — | -$0.05 |
 Gene Biotherapeutics, Inc. CRXM | $0M | N/A | — | -$0.02 |
 American CryoStem Corporation CRYO | $0M | N/A | — | -$0.05 |
 E-Qure Corp. EQUR | $0M | N/A | — | -$0.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Capha Pharmaceuticals Inc. (FPSUF) measures how much investors pay for each dollar of the company's trailing earnings. FPSUF's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
FPSUF pe ratio · 6 questionsFPSUF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via FPSUF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Capha Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09